Table 1.
Results of individual investigations at first visit and follow-up.
| Parameter | First visit | Follow-up |
|---|---|---|
| CSF analysis | ||
| Cell count /ul (pathological: >5 µl) | 8 | 8 |
| Lymphocytes in % | 93 | 92 |
| Monocytes in % | 5 | . |
| Plasma cells in % | 2 | 2 |
| Albumin mg/L | 518 | 615 |
| IgG mg/L | 69.3 | 62.5 |
| IgA mg/L | 10.7 | 9.6 |
| IgM mg/L | 0.97 | 0.84 |
| QAlb % | 11.5 | 15.4 |
| QIgG % | 7.3 | 8.9 |
| QIgA % | 4.3 | 5.2 |
| QIgM % | 2.4 | 2.4 |
| Lactat mmol/L | 2 | 2 |
| Oligoclonal IgG | – | – |
| NSE ng/ml (pathological: >30 ng/ml) | 19.3 | . |
| S100 µg/ml (pathological: >2.7 µg/ml) | 2 | . |
| Tau pg/ml (pathological: >450 pg/ml) | 409 | . |
| P-Tau 181 pg/ml (pathological: > 61 pg/ml) | 68 | . |
| Aß1-42 pg/ml (pathological: >450 pg/ml) | 715 | . |
| Aß1-40 pg/ml | 9565 | . |
| Aß ratio pg/ml (pathological: >0.5 pg/ml) | 0.75 | . |
| Serum | ||
| Oligoclonal IgG | – | – |
| CRP mg/l | 42.5 | 1.1 |
| Leukocytes 103 µl | 5.63 | 4.29 |
| Neuropsychological testing* | ||
| MMSE | 30 | 29 |
| CDT | 01 | 01 |
| CERAD Boston Naming Test | PR 31 | PR 82 |
| CERAD semantic fluency | PR 50 | PR 66 |
| CERAD phonemic fluency | PR 82 | PR 62 |
| TMT part A | PR 76 | PR 99 |
| WAIS-IV Digit Symbol Test | PR 84 | PR 95 |
| TMT division part B/A | PR 84 | PR 58 |
| RWT semantic fluency (alternating) | PR 30 | PR 75 |
| RWT phonemic fluency (alternating) | PR 63 | PR 54 |
| WAIS-IV Digit Span forward | PR 05* | PR 05* |
| WAIS-IV Digit Span backward | PR 16 | PR 16 |
| CERAD List Learning (trials 1-3) | PR 34 | PR 34 |
| CERAD List Recall (savings) | PR 46 | PR 54 |
| CERAD List Recognition/discriminability | PR 21 | PR 79 |
| WMS-IV Logical Memory I | PR 50 | PR 50 |
| WMS-IV Logical Memory II | PR 16 | PR 50 |
| CERAD Figure recall (savings) | PR 01* | PR 12* |
| WMS-IV Visual Reproduction I | PR 25 | PR 50 |
| WMS-IV Visual Reproduction II | PR 50 | PR 75 |
| CERAD Figure Copy | PR 73 | PR 18 |
| ROCFT Copy | PR>16 | PR>16 |
| WAIS-IV Block Design | PR 25 | PR 75 |
| Psychopathology | ||
| BDI-II | 04 | 05 |
| Polysomnography | ||
| Apnoe-Hypopnoe-Index | . | 9.7 |
| PLMI | . | 64.6 |
| Basal 02 desaturation % | . | 94 |
| Minimal 02 desaturation % | . | 89.0 |
| 02 desaturation index % | . | 13 |
*For better comparison, cognitive data is presented as percentiles (PR) unless otherwise indicated. Asterisk denote performance below the normal range (PR<16). . = data not available. - = not present. Polysomnography data are derived from the second night.
AHI, apnoe-hyperpnoe index; Aß ratio, ß amyloid 1-42/1-40 ratio; Aß1-40, ß amyloid 1-40; Aß1-42, ß amyloid 1-42; BDI-II, Beck Depression Inventory; CSF, cerebrospinal fluid; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; MMSE, Mini-Mental Status Examination; CDT, Clock Drawing Test; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; TMT, Trail Making Test; RWT, ROCFT, Rey-Osterrieth-Complex-Figure test; WAIS-IV, Wechsler Adult Intelligence Scale IV; WMS-IV, Wechsler Memory-Scale IV, NSE, neuron specific enolase; O2 desaturation, oxygen desaturation; PLMI, periodic limb movement index; P-tau181, phosphorylated tau protein 181; QAlb, quotient albumin; QIgA, quotient immunoglobulin A; QIgG, quotient immunoglobulin G; QIgM, quotient immunoglobulin M; T-tau, total tau protein.